VivoSeq
Metabolic & Endocrine

Uncontrolled Gout

2

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Uncontrolled Gout is an early-stage landscape with 2 programs across 3 companies. The most active players are Horizon Therapeutics Ireland DAC, Alnylam Pharmaceuticals, Amgen. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Horizon Therapeutics Ireland DAC

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3Amgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Pegloticase

Horizon Therapeutics Ireland DAC

Methotrexate

Alnylam Pharmaceuticals

Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Protein / enzyme150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

7

clinical trials

Completed5 · 71%
Recruiting2 · 29%

Clinical Trials

Trial Activity

7 trials

A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.
Recruiting·SShanghai Institute Of Biological Products·Phase 1·NCT06298071·36 enrolled
A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout
Recruiting·Amgen logoAmgen·Phase 3·NCT07388498·270 enrolled
Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
Completed·Amgen logoAmgen·Phase 4·NCT04772313·11 enrolled
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Completed·Amgen logoAmgen·Phase 4·NCT03994731·152 enrolled
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
Completed·Amgen logoAmgen·Phase 4·NCT04762498·50 enrolled
Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate
Completed·Amgen logoAmgen·Phase 4·NCT04511702·191 enrolled
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
Completed·Amgen logoAmgen·Phase 4·NCT03635957·14 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)